Condition: Early Syphilis, Latent, Serological Relapse After Treatment · Sponsor: National Taiwan University Hospital
This randomized controlled superiority study will be conducted during 2023-2025. The eligible participants are adult people living with HIV (PLWH) who are newly diagnosed with early syphilis. Participants will be randomized in a 1:1 ratio to receive single-dose benzathine penicillin G (BPG) (2.4 MU intramuscularly once) plus doxycycline (100 mg orally twice daily for 7 days) or single-dose BPG. The primary outcome is serologic response, defined as a decline of rapid plasma reagin (RPR) titer by 4-fold or greater, at week 24 and week 48; and the secondary outcomes include microbiologic response of syphilis and bacterial sexually transmitted infections (STIs) assessed by nucleic-acid amplification test (NAAT) at week 4.
This description comes directly from the study's public registry record.
Kuan-Yin Lin, MD · +886-975607715 · kuanyin0828@gmail.com
Always discuss trial participation with your own doctor first.
| National Taiwan University Hospital Hsin-Chu Branch | Hsinchu, Taiwan, Taiwan | Recruiting |
| Far Eastern Memorial Hospital | Taipei, Taiwan, Taiwan | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan, Taiwan | Recruiting |
| Taipei Vetetrans General Hospital | Taipei, Taiwan, Taiwan | Recruiting |
| Taoyuan General Hospital | Taoyuan, Taiwan, Taiwan | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Recruiting |
| Kaohsiung Veterans General Hospital | Kaohsiung City, Taiwan | Recruiting |
| Chi Mei Medical Hospital | Tainan, Taiwan | Recruiting |
| National Cheng-Kung University Hospital | Tainan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06069141